Home › NDC Lookup › Ingredients › Enoxaparin Sodium › 63323-0559-65
💉image loading
(from DailyMed)

Enoxaparin Sodium 30 mg/.3mL Injection — NDC 63323-559-65 (Billing 63323-0559-65)

by Fresenius Kabi USA, LLC · 10 BLISTER PACK in 1 CARTON / 1 SYRINGE in 1 BLISTER PACK / .3 mL in 1 SYRINGE

This is a package of Enoxaparin Sodium 30 mg/.3mL Injection from Fresenius Kabi USA, LLC, marketed since Apr 2019 and currently FDA-listed; retail pharmacies pay about $9.13 per mL (NADAC).

NDC 63323-0559-65
🏷️ FDA NDC (as labeled) 63323-559-65 billing pads the product segment with a zero
This package
Contains.3 mL in 1 syringe Cost per mL$9.13 NADAC Per package$27.38 / 3 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $13.82/unit · Part D plans $10.33/unit — full pricing hub ↓
Product page 63323-0559-93 Also comes in: 1 syringe 63323-559-93
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 63323-559-65 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
63323 labeler · 559 product · 65 package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 6332355965 6
Medicaid fills, this package
60 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Enoxaparin Sodium (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 5, 2025 — Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL (Cardinal Health Inc.) · FDA recall D-0597-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 63323-559-65
Product NDC 63323-559
11-digit billing NDC 63323055965
NCPDP billing unit ML — per mL (volume)
Application # ANDA078990
SPL Set ID 2180fa77-eb24-47ef-9c46-b144965fa4c6
Established class (EPC) Heparin; Low Molecular Weight Heparin
Chemical class Low-Molecular-Weight
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-04-23
Route SUBCUTANEOUS
Dosage form INJECTION
Substance ENOXAPARIN SODIUM
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 019331
GCN 00420
HICL code 007878
Ingredient (HICL) Enoxaparin Sodium
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M9
Therapeutic class — intermediate (HIC2) Drugs Given To Alter Blood Coagulation
HIC3 code M9K
Therapeutic class — specific (HIC3) Heparin And Related Preparations
AHFS code 20:12.04.16
AHFS class Heparins
FDB label name ENOXAPARIN 30 MG/0.3 ML SYR
FDB brand name Enoxaparin Sodium
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 019331
  • GCN: 00420
  • HICL (First Databank): 007878
  • AHFS class code: 20:12.04.16
Why two NDCs? The FDA registers this code as 63323-559-65 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 63323-0559-65. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ENOXAPARIN 30 MG/0.3 ML SYR Ingredient Enoxaparin Sodium
📖 What it is MedlinePlus · NLM

Enoxaparin is used to prevent and treat deep vein thrombosis (DVT; blood clots that form in the veins, typically in the legs). It is also used to prevent complications from angina (chest pain) and heart attacks. Enoxaparin is in a class of medications called low molecular weight heparins. It works by stopping the formation of substances that cause clots.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is a blood thinner that helps prevent and treat deep vein thrombosis, a clot in a deep vein. It is also used in unstable angina and certain heart attacks. Your prescriber choose...
  • It is an injection, usually under the skin, and some uses involve an injection into a vein. How often depends on why you need it. Follow your prescriber’s directions and the produc...
  • Bruising, injection site pain, nausea and diarrhea are common. Some people have bleeding or a lower blood count. Call your doctor if bleeding seems unusual or won’t stop.
  • Yes. If you have an epidural or spinal procedure, bleeding near the spine can rarely cause permanent paralysis. Report new numbness, leg weakness or bladder or bowel changes right...
📖 Read our full Enoxaparin guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
1
Nutrient depletion considerations

Enoxaparin may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Enoxaparin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $9.127 $27.38 / 3 ml
Medicaid paysCMS SDUD · 12 mo $13.82 $41.46 / 3 ml
Medicare drug plans payPart D · Q2 2026 $10.33 $31.00 / 3 ml
Medicare Part B allowsASP · J1650 $0.536 / J1650 unit —
NADAC price history (per mL) — tap or hover for the price & month
Jun 2022 Dec 2023 Mar 2026 Sep 2026 $14.159 $8.661
▼ Down 33% over the last 19 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)63323-559-65
11-digit billing NDC63323-0559-65
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ1650
DescriptorINJECTION, ENOXAPARIN SODIUM, 10 MG
Billing units / pkg10 units
How the units are derivedThis package is 0.3 ML; the HCPCS unit is 10 MG, so one package = 10 billing units.
Medicare Part B spend (2026 (Q1))$24,269 · 288 claims · $84.27 per claim (all NDCs under J1650)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
63323-0559-65 You're viewing this 10 BLISTER PACK in 1 CARTON / 1 SYRINGE in 1 BLISTER PACK / .3 mL in 1 SYRINGE $9.13 / mL $27.38 2019-04-23 — Active
63323-0559-93 63323-559-93 Main listing 10 BLISTER PACK in 1 CARTON / 1 SYRINGE in 1 BLISTER PACK / .3 mL in 1 SYRINGE $9.13 / mL $27.38 2019-04-23 — Active

This pack has the lowest per-mL cost of the 2 priced pack sizes ($9.13 NADAC).

This pack accounts for about 13% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 blister pack in 1 carton / 1 syringe in 1 blister pack / .3 ml in 1 syringe.
What NDC number is used to bill for this package of Enoxaparin Sodium 30 mg/.3mL Injection?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Enoxaparin Sodium 100 mg/mL 00548-5601-00 Amphastar 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 100 mg/mL 00781-3238-63 Sandoz 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 100 mg/mL 16714-0006-10 NorthStar 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 100 mg/mL 25021-0410-70 Sagent 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 30 mg/.3mLthis 63323-0559-65 Fresenius 1 syringe $9.127 AP Availability likely —
Enoxaparin Sodium 100 mg/mL 68001-0457-42 BluePoint 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 100 mg/mL 68001-0633-42 BluePoint 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 30 mg/.3mL 70710-1757-06 Zydus 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 100 mg/mL 71288-0432-92 Meitheal 10 syringes $9.127 AP Availability likely —
enoxaparin sodium 30 mg/.3mL 71839-0109-10 BE 10 syringes $9.127 AP Availability likely —
Enoxaparin Sodium 30 mg/.3mL 81952-0123-23 Hepalink 10 syringes $9.127 AP Availability likely —
Enoxaparin sodium 30 mg/.3mL 00955-1003-10 Sanofi-Aventis 10 cellos $9.127 AP Availability likely —
Enoxaparin Sodium 30 mg/.3mL 63323-0533-93 Fresenius 10 cellos $13.117 AP FDA listed +44%
Enoxaparin Sodium 30 mg/.3mL 72603-0165-10 NorthStar 10 syringes $13.117 AP FDA listed +44%
Lovenox 30 mg/.3mL 00075-0624-30 Sanofi-Aventis 10 cellos — AP FDA listed —
Lovenox 30 mg/.3mL 00075-8013-10 Sanofi-Aventis 10 cellos — AP FDA listed —
Enoxaparin Sodium 30 mg/.3mL 11797-0757-06 Italfarmaco 10 syringes — AP FDA listed —
enoxaparin sodium 30 mg/.3mL 28955-0101-10 Hebei 10 syringes — AP FDA listed —
Enoxaparin Sodium 100 mg/mL 55154-3540-05 Cardinal 5 syringes — AP FDA listed —
Enoxaparin Sodium 30 mg/.3mL 68083-0634-10 Gland 10 syringes — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Apr 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Enoxaparin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerFresenius Kabi USA, LLC
Application holderGLAND PHARMA LTD
FDA applicationANDA078990 (ANDA)
Labeler code63323
First marketedApr 2019
Product typeHuman Prescription Drug
Portfolio556 products on file

More NDCs from Fresenius Kabi USA, LLC labeler code 63323

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
60
Units reimbursed last 4 qtrs
24
Gross reimbursed last 4 qtrs
$331.68
Avg / prescription
$5.53
Avg / unit
$14.1140
Latest quarter Q1 2026
0Rx
Medicaid pays / mL
$14.1140
gross reimbursed
vs
NADAC / mL
$9.1268
acquisition cost
=
Spread
+$4.9872
+55% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
20% FFS 80% MCO
Fee-for-service · 12 Rx Managed care · 48 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 7 units · 0.1 per 100k residents OH Pennsylvania: 5 units · 0.0 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 6 units · 0.0 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 5 units · 0.0 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.00.1
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Ohio 0.1 /100k
2 Pennsylvania 0.0 /100k
3 Texas 0.0 /100k
4 California 0.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 syringe63323-0559-93 405 Rx · $2,938
1 syringe this page63323-0559-65 60 Rx · $332
Drug total (last 4 qtrs): 465 Rx · 377 units · $3,270 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Enoxaparin Sodium — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Enoxaparin Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$20.1M
Claims incl. refills
131.2K
Beneficiaries
84K
Spend / beneficiary
$239.28
Spend / claim
$153.24
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 63323-0543-13 · Fresenius 63323-0562-15 · Fresenius →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.